Omnicell, Inc. (OMCL) — ESG & Values Scores

Environment story

Omnicell discloses minimal environmental performance data. No Scope 1, 2, or 3 emissions figures are disclosed in the 10-K or accompanying materials. No net-zero target year is stated. The company mentions tariff mitigation through nearshoring and dual-sourcing but provides no verified decarbonization infrastructure investments. No resource controversies (water, toxic waste, habitat) are flagged in filings. Without disclosed emissions baselines or reduction targets, environmental performance cannot be rigorously assessed. The company risks greenwashing by remaining silent on material climate impacts while competing in healthcare, a carbon-intensive sector.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Supply Chain Nearshoring & Dual-Sourcing

Omnicell implemented dual-sourcing of components and nearshoring of manufacturing to mitigate tariff impacts, suggesting some operational efficiency focus.

Marginal; tariff mitigation is cost-driven, not climate-motivated.

Social story

Omnicell reports ~3,580 full-time employees as of December 31, 2025. No CEO-to-worker pay ratio is disclosed; this metric cannot be verified from the 10-K. No documented union-suppression activities or strikes within 24 months are disclosed. Leadership diversity metrics (executive/board representation by gender or race) are not disclosed in the filing. No supply-chain human-rights audits or conflict-mineral policies are mentioned. The company acknowledges workforce risks including recruitment and retention challenges, and notes healthcare labor shortages as a business opportunity (addressing pharmacy technician and compounding deficits). No formal labor union standing, diversity commitments, or supply-chain ethics frameworks are disclosed. Overall, social governance disclosures are sparse and do not meet emerging ESG transparency standards.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Workforce Development & Recruitment

Company identifies healthcare labor shortages (88% of hospitals report technician deficits, 92% lack sterile compounding expertise) as a driver for automation solutions, indirectly supporting professional development.

Indirect; addresses industry labor challenge rather than direct employee benefit.

Governance story

Omnicell operates under a single-class share structure with no disclosed dual-class voting provisions, supporting governance neutrality on that dimension. Board independence percentage is not disclosed in the 10-K. The company settled a False Claims Act violation with the U.S. Attorney's Office for the Eastern District of Washington on May 5, 2025, paying $4.6 million without admission of liability for potential non-compliances with Federal Supply Schedule contracts. The settlement signals prior compliance gaps but resolution without admission limits severity scoring. No active antitrust or consumer-safety proceedings are disclosed. Lobbying expenditures and political contributions are not disclosed. The company does not report lobbying targeting environmental deregulation or consumer-protection rollbacks. Overall governance transparency on board composition, political activity, and lobbying spend is deficient.

Criticisms on file

False Claims Act Settlement
Source: Omnicell 10-K Item 1A Risk Factors and Item 7 MD&A; disclosed May 5, 2025 settlement with U.S. Attorney's Office Eastern District of Washington for $4.6 million related to Federal Supply Schedule contract non-compliance and False Claims Act violations.

Disclosed initiatives

Compliance & Governance Framework

Company maintains policies, procedures, and controls for handling regulated patient health information under HIPAA and state privacy laws. Operates under Second Amended and Restated Credit Agreement with Wells Fargo as administrative agent, including covenants and compliance monitoring.

Standard; reflects regulatory compliance obligation rather than exemplary governance.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Omnicell, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Omnicell, Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)